For many firms, the first instinct in mass tort marketing is to focus on ad volume: more impressions, more clicks, more calls, more form fills. That focus is understandable. Competitive torts move quickly, media costs can fluctuate, and firms often need claimant...
Mass tort marketing in 2026 is not just about finding the next big litigation. It is about understanding where claimant volume, court activity, advertising competition, and operational pressure are concentrating. The federal MDL system remains a major engine of mass...
For mass tort firms looking for the next emerging docket with real upside, Depo-Provera has moved beyond the watch-list stage. This is no longer just a theory drawing plaintiff interest. The litigation now has three signs of a docket worth serious attention: MDL...
Introduction Aqueous Film-Forming Foam (AFFF), once considered essential for combating fuel-based fires, is now at the center of one of the fastest-growing mass tort litigations in the United States. Thousands of lawsuits allege that exposure to toxic “forever...
Introduction Litigation involving infant formula and necrotizing enterocolitis (NEC) continues to expand in 2026, with hundreds of lawsuits filed across the U.S. Parents of premature infants allege that cow’s milk–based formulas increased the risk of this...
A Year That Redefined the Mass Tort Playbook Introduction The mass tort landscape in 2025 marked a clear turning point for plaintiffs firms. Traditional assumptions about volume, MDL momentum, and broad sign-ups were challenged as courts tightened standards, new...